The oxygen-sensing prolyl hydroxylase domain (PHD) enzymes are key to maintaining tissue homeostasis during hypoxia via their regulation of the expression and activity of HIF, the master transcription factor for the hypoxic response. In this issue of the JCI, Yamamoto, Hester, and colleagues show that temporal and reversible inhibition of PHD2 in vivo leads to systemic autoimmune disorder. The work demonstrates that a reduction of PHD2 leads to impairment of immunosuppressive Treg function via a HIF2a-dependent mechanism, without altering Foxp3 expression. This study indicates that a PHD2/HIF2a axis is critical for maintaining proper Treg function.
Oxygen-sensing pathways
The cellular response to hypoxia is regulated by the heterodimeric transcription factor HIF. HIF consists of a constitutively expressed HIF1β subunit, which is encoded by the aryl hydrocarbon receptor nuclear translocator (ARNT) gene, and an oxygen-sensitive HIFα subunit. The two best-characterized α subunits are HIF1α and HIF2α (1) . HIF is regulated by oxygen via the action of prolyl hydroxylase domain (PHD) enzymes, which are ironand α-ketoglutarate-dependent dioxygenases that utilize molecular O 2 for hydroxylation reactions. Under adequate cellular oxygen, iron, and α-ketoglutarate levels, PHDs hydroxylate HIFα on conserved proline residues. Hydroxylation leads to the binding of von Hippel-Lindau (VHL) protein and recruitment of an E3 ubiquitin ligase complex, resulting in rapid degradation of HIF (2) . During hypoxia, HIFα is stabilized, binds to ARNT, and regulates target genes that control angiogenesis, cellular metabolism, iron handling, survival, proliferation, and migration. The three PHD isoforms PHD1, PHD2, and PHD3 (also termed EGLN2, EGLN1, and EGLN3, respectively) have overlapping but unique tissue expression patterns. PHD2 is ubiquitously expressed, and whole-body disruption of PHD2 leads to early embryonic lethality. PHD1 and PHD3 are more selectively expressed, and mice with whole-body knockout of PHD1 or PHD3 are viable (3) . The role of HIF signaling in the immune system has been a subject of intense research and debate, but the mechanisms have remained unclear.
Oxygen-sensing pathways in immune cells
Tissue hypoxia and HIF activation occur following tissue injury, infection, inflammation, and rapid tumor growth. Resident or recruited immune cells must rapidly activate HIF to adapt and function in a hypoxic environment. In tissues that demonstrate a basal hypoxic response (e.g., the intestine), physiological HIF expression is essential to maintain immune tolerance and function, which are critical for tissue homeostasis (4) . During a robust injury or in the setting of chronic inflammation, including cancer, pathological hypoxia via constitutive HIF expression leads to the activation of proinflammatory mediators and tissue damage. The role of hypoxia and HIF activation in immune cells is complex and may be celltype dependent. It is clear that hypoxia and HIF signaling affect metabolic pathways, in particular by inducing glycolytic gene expression, but the functional responses differ in different cell types. Therefore, many studies have utilized Cre-mediated deletion to understand the role of HIFs in individual immune cell populations, which have demonstrated the cell-autonomous dependency of HIFs in modulating immune cell function. However, those studies lacked temporal regulation, and because of lineage-and developmental stage-specific activation of various Cre recombinases, the results have at times been discordant (5) (6) (7) (8) (9) (10) (11) (12) . Furthermore, the approach of targeting HIF function in specific cell types does not address the role of heterocellular crosstalk in the response to hypoxia in the inflammatory or injured foci or in cancer.
In this issue, Yamamoto, Hester, and colleagues developed an inducible mouse model to assess the hypoxia/HIF pathway using an RNA interference knockdown approach in vivo (13) . Specifically, they cloned reverse tetracycline transactivator (rtTA) driven by the endogenous ROSA26 promoter and a single-copy tetracycline response element (TRE) controlling a GFP-shRNA cassette expressing an shRNA sequence for PHD2, HIF1α, or HIF2α downstream of the collagen type I (Col1a1) gene. Upon doxycycline treatment, the mice expressed the shRNAs and GFP, enabling temporal and reversible gene silencing and cellular tracking in adult mice (Figure 1) . The authors found that mice with knockdown of Phd2 became grossly sick, characterized by weight loss, alopecia, and anemia. The anemia was surprising, as HIF activation is known to increase erythropoi-
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PHD2, Tregs, and autoimmunity
The phenotype of the shPhd2 mice was consistent with that of a progressive autoimmune disorder. To determine whether what they observed was immune cell autonomous, the authors generated bone marrow chimeras and showed that transfer of hemopoietic cells from shPhd2 mice was sufficient to induce the immune phenotype in the recipients. Examination of T cell subsets in shPhd2 mice revealed an increase in the absolute numbers of these cells, including a surprising increase in the number of Tregs, which maintain homeostasis and self-tolerance. Despite this finding, shPhd2 mice resembled other models with gross pathologies associated with disruption of Tregs.
weeks following disruption of Phd2, the mice exhibited peripheral lymphadenopathy and increased leukocytes, although the phenotype was less severe than that observed in the shPhd2 mice. The leukocytosis, lymphoid expansion, and immune dysregulation were reversed when doxycycline treatment was removed, indicating acute and reversible regulation of the response by PHD2. Likewise, simultaneous knockdown of Phd2 and Hif2a rescued the effect of Phd2 knockdown (whereas simultaneous knockdown of Phd2 and Hif1a did not), demonstrating that the phenotype was at least partially dependent on HIF2α. The affinity and tissue specificity of the three PHDs for HIF1α and HIF2α in vivo are currently not known but could contribute to the selectivity of HIF activation following hypoxia. esis by direct activation of erythropoietin, leading to increased iron absorption (14, 15) . However, shPhd2 mice demonstrated lymphadenopathy, splenomegaly, and expansion of lymphoid compartments. Prominent immune infiltrates, inflammation, and injury were observed in a number of tissues. The findings were consistent in two transgenic lines with two different shRNAs targeting PHD2. It should be noted that this phenotype differs from reports of whole-body Cre-mediated inactivation of Phd2 in adult mice, which led to death due to robust global changes in erythropoiesis and metabolism (16, 17) . However, in a complementary approach, Yamamoto, Hester, and colleagues crossed tamoxifen-inducible Cre recombinase (Rosa26Cre ERT2 ) mice with Phd2 fl/fl mice and showed that four In the presence of doxycycline, transgenic mice show increased expression of shRNA for PHD2 in all tissues. shRNA for PHD2 (shPhd2) stabilizes HIF2α in the hemopoietic compartment, leading to complete loss of the immunosuppressive function of Tregs. No changes in Foxp3 expression or Treg numbers, but an increase in T-bet and TNF-α expression, were observed following shPhd2 expression. The mice had a progressive autoimmune disorder, which was completely reversible following the removal of doxycycline (DOX). CAG, chicken β-actin.
with chronic kidney disease (CKD), for whom the inhibitors are intended to stimulate erythropoiesis to improve anemia. PHD inhibitors have so far been shown to be safe and effective in preclinical models and in patients (22) . Recently, a battery of publications has shown that PHD inhibitors are beneficial in models of intestinal inflammation (23) , and there is interest in assessing their action in patients with inflammatory bowel disease, which may require higher doses than those used to treat CKD. The work of Yamamoto, Hester, and coworkers argues for some caution and suggests that it will be important to monitor Treg function in patients treated with PHD inhibitors. Furthermore, since PHD inhibitors may affect Tregs, it would be interesting to test the antitumor potential of these drugs in syngenic models of cancer. In summary, the work highlights the need for further studies of the role of PHD2 and HIF2α inhibitors in autoimmune disorders, inflammation, and cancer.
